Exhibit 99.1 Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update - Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., August 13, 2024 (G ...

VG-3927 Clinical Trial Progress - VG-3927 demonstrates potential as a differentiated approach to treating Alzheimer's disease (AD) with improved safety and efficacy, addressing multiple aspects of AD pathophysiology [1] - The ongoing Phase 1 trial has enrolled 80 healthy volunteers, with 60 receiving VG-3927 across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts as of June 30, 2024 [1] - Interim data shows VG-3927 achieved a robust decrease in sTREM2 in cerebrospinal fluid (CSF), demonstrating clinical proof-of-target engagement [3] - VG-3927's safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile supports its continued development as a potential once-daily oral therapy for AD [3][8] - The company plans to report complete Phase 1 data, including data from the AD patient cohort, in Q1 2025 [3][9] VG-3927 Mechanism and Biomarker Data - VG-3927 acts as a TREM2 agonist, converting microglia into a neuroprotective state, supported by preclinical and clinical data [3] - VG-3927 showed a predictable PK profile supportive of once-daily dosing and a sustained decrease in sTREM2 in CSF across SAD and MAD cohorts [5] - Repeat dosing of VG-3927 increased osteopontin/secreted phosphoprotein 1 (SPP1), a biomarker associated with neuroprotective microglia [5] - No effect on soluble Colony Stimulating Factor 1 Receptor (sCSF1R), a microglial trophic factor, has been observed to date [5] Company Strategy and Pipeline - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring microglia function [6] - The company's lead candidate, iluzanebart, is a monoclonal antibody targeting TREM2 for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) [6] - VG-3927, a small molecule TREM2 agonist, is being developed for AD and other neurodegenerative diseases associated with microglial dysfunction [6] Upcoming Presentations and Data Releases - Vigil plans to present new preclinical and clinical data from the VG-3927 SAD cohorts at the 2024 Alzheimer's Association International Conference (AAIC) [7][8] - The company has commenced screening for an AD patient cohort in the Phase 1 trial to explore biomarker responses after a single dose of VG-3927 [9]

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations highlighting its oral small molecule VG-3927 at the 2024 Alzheimer's Association International Conference (AAIC) taking place on July 28-August 1, 2024 in Philadelphia, Pennsylvania and virtually. Title: Pharmacological and functi ...

Details of the oral presentation are as follows: Details of the poster presentations are as follows: Title: Pharmacological and functional characterization of the first small molecule TREM2 agonist, VG-3927, for the treatment of Alzheimer's disease Presented by: Borislav Dejanovic, Ph.D., Vigil Neuroscience Date and Time: Sunday, July 28, 2024, 8:00 AM – 4:15 PM EDT (Poster location Sunday-77) About Vigil Neuroscience Vigil Neuroscience routinely posts information that may be important to investors in the ' ...

"We are updating our clinical development strategy to preserve the IGNITE dataset for a final analysis at 12 months, which we believe provides the best opportunity to leverage our biomarker strategy and to pursue the potential accelerated approval pathway. As part of this strategy, we will not conduct an interim analysis prior to the study completion," said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "This follows a Type C meeting with the FDA where the Agency sta ...

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today an update following a Type C Meeting with the U.S. Food and Drug Administration (FDA) to its clinical development strategy for its IGNITE clinical trial evaluating iluzanebart in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALS ...

NEW YORK, July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions. Purcell & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types ...

Vigil Neuroscience (NASDAQ:VIGL) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ:SNY). As part of this investment agreement, Vigil Neuroscience is granting Sanofi exclusive right of first negotiation (ROFN) for its molecule TREM2 agonist program. This covers the exclusive license, grant or transfer of rights to research, development, manufacturing and commercialization. Vigil Neuroscience president and CEO Iva ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-41200 VIGIL NEUROSCIENCE, INC. (Exact name of Registrant as specified in its Charter) De ...

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update – Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 7, 2024 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microgli ...